Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) | |
US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) |
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7955619 | DAIICHI SANKYO INC | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
US10314788 | DAIICHI SANKYO INC | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) |
Market Authorisation Date: 02 October, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(10 years from now) | |
US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(10 years from now) | |
US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(10 years from now) |
Market Authorisation Date: 30 October, 2013
Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic